GlaxoSmithKline plc is anticipating that demand for its shingles vaccine, depressed over the past year due to COVID-19, will pick up again in the second half of the year and 2022; the company is looking toward that vaccine resilience as well as pipeline development to carry it past its pandemic depression.
The London-based drug maker announced its first quarter earnings on 28 April, with sales coming in well below analysts’ expectations...








